Phase III trial

Liver cancer
#AACR 2023 #Cancer research #Cancer treatment #Liver cancer #Oncology #Phase III trial

Results revealed for ‘practice-changing’ combination liver cancer therapy

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023,… Read More

#Cancer Research #News

Haematology
#Cell and gene therapy #CSL #Gene therapy #Haemophilia #MHRA #Phase III trial

First gene therapy for haemophilia B approved in Great Britain

CSL’s Hemgenix (etranacogene dezaparvovec) has been authorised as the first gene therapy for adults with severe and moderately severe haemophilia B (congenital Factor IX (FIX) deficiency) in Great Britain. It has been granted a marketing authorisation for patients without a history of FIX inhibitors by the UK Medicines and Healthcare… Read More

#News #Regulatory

Doctor showing a model of the prostate
#Cancer research #Oncology #Phase III trial #Prostate cancer

Positive Phase III results for prostate cancer drug

Pfizer and Astellas have announced positive top-line results from the Phase III EMBARK trial evaluating XTANDI (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial were randomised to one of three study arms: XTANDI plus leuprolide,… Read More

#Cancer Research #News

Male patient with doctor
#Cancer research #CHMP #European Medicines Agency #Gene mutation #Oncology #Phase III trial #Prostate cancer

Prostate cancer combination therapy reduces risk of death

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.  Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by the Committee for… Read More

#News #Regulatory

Clostridioides difficile
#Collaboration #Destiny Pharma #Partnership #Phase III trial #Sebela Pharmaceuticals

Companies agree up to $570m deal for C difficile drug

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence.  It is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America.   Destiny will keep most rights… Read More

#Business & Investment #News

Vaccine
#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Phase III trial #Vaxxinity

New Covid-19 booster outperforms approved vaccines

Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).  The results show UB-612 elicits superior neutralising antibody titers and seroconversion rates against… Read More

#News #Trending News

Prostate cancer cells
#Cancer research #Genetics / genomics #Janssen #Oncology #Phase III trial #Prostate cancer

PARP inhibitor slows progression in HRR-positive prostate cancer

Janssen has revealed updated results from the Phase III MAGNITUDE study, which show that a combination therapy including niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, slowed prostate cancer progression.  The drug was investigated in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate… Read More

#Cancer Research #News

Stamp of approval
#European Commission #Orphan drugs #Paediatrics #Phase III trial #Regulatory #UCB

Fenfluramine approved in the EU for LGS seizures

UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).  It has received authorisation as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.  The approval was based on safety and… Read More

#News #Regulatory

#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Drug development #Drug discovery #Oncology #Phase III trial

This week in drug discovery (6-10 February)

News round-up for 6-10 February by DDW Digital Content Editor Diana Spencer.  Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient… Read More

#News

T cell attacking cancer cell
#Atara Biotherapeutics #Epstein-Barr virus #EU #European Commission #Immunotherapy #Phase III trial #Pierre Fabre #T cell activation

First allogeneic T cell immunotherapy launched in EU

Pierre Fabre will commercialise and distribute the first approved allogeneic T cell immunotherapy in Europe following the transfer of the European Commission marketing authorisation of Ebvallo (tabelecleucel) from Atara Biotherapeutics.  Ebvallo is the only approved therapy for the treatment of relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+… Read More

#Business & Investment #News

#Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology #Phase III trial

Immunotherapy offers survival extension for brain tumour patients

Listen to this article on the DDW Podcast: Why data from a Phase III clinical trial offers promise for patients with a deadly form of brain cancer. A Phase III clinical trial has produced promising results for a cancer vaccine targeting patients with a new or recurrent glioblastoma.  The study, which… Read More

#Cancer Research #Exclusive Content

Mosquito
#Immunology / Virology & Vaccines #MHRA #Phase III trial #Takeda #Vaccine candidate

UK approval for dengue virus vaccine candidate

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age.  Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019… Read More

#News

Plaque psoriasis
#Bristol Myers Squibb #CHMP #Dermatology #European Medicines Agency #Phase III trial

First oral allosteric TYK2 inhibitor recommended in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.   Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment… Read More

#News #Regulatory

#CHMP #EMA #Ipsen #Marketing approval authorisation #Phase III trial #Regulatory

CHMP rejects rare bone disease treatment in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorisation for Ipsen’s investigational palovarotene as a treatment for fibrodysplasia ossificans progressiva (FOP).   The company says it will be requesting a re-examination of the CHMP opinion, based on scientific… Read More

#News #Regulatory

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

DDW Highlights podcast: 23 January 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Clinical trials have led our news section this week, with positive results… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

This week in drug discovery (16-20 January)

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not… Read More

#News